IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

* Discussions with FDA advance toward expected marketing authorization for GraftAssureDx * FDA completes current portion of substantive review in a timely manner * Favorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunity * Strong head-to-head data drive kitted customer interest NASHVILLE, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results:

We continue to be encouraged by progress toward our most important priority, which is to attain regulatory authorization of GraftAssureDx.